Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2023-05-11 00:00:00 ET · period of report 2023-04-28 · accession 0001209191-23-028813 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-11 | 2023-05-09+ | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +60.0K | 456.2K | +15% | +$4.07M |
| DM | 2023-05-11 | 2023-05-09+ | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $94.89 | -60.0K | 426.2K | -12% | -$5.69M |
| D | 2023-05-11 | 2023-04-28 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $66.88 | +317 | 426.2K | +0.1% | +$21.2K |
| DM | 2023-05-11 | 2023-05-09 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $0.00 | -60.0K | 69.1K | -46% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-09 | M | A | 30,000 | $67.81 | 456,213 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. |
| 2 | Common | Common Stock | 2023-05-09 | S | D | 13,626 | $94.22 | 442,587 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F3) The price in column 4 is the weighted average price. The price actually received ranged from $93.85 to $94.83. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 3 | Common | Common Stock | 2023-04-28 | A | A | 317 | $66.88 | 426,213 | D | — | — | (F1) Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan. |
| 4 | Common | Common Stock | 2023-05-09 | S | D | 14,964 | $95.49 | 427,623 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F4) The price in column 4 is the weighted average price. The price actually received ranged from $94.86 to $95.85. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 5 | Common | Common Stock | 2023-05-09 | S | D | 1,410 | $95.90 | 426,213 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F5) The price in column 4 is the weighted average price. The price actually received ranged from $95.86 to $95.97. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 6 | Common | Common Stock | 2023-05-10 | M | A | 30,000 | $67.81 | 456,213 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. |
| 7 | Common | Common Stock | 2023-05-10 | S | D | 21,453 | $94.65 | 434,760 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F6) The price in column 4 is the weighted average price. The price actually received ranged from $94.12 to $95.11. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 8 | Common | Common Stock | 2023-05-10 | S | D | 8,547 | $95.34 | 426,213 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F7) The price in column 4 is the weighted average price. The price actually received ranged from $95.115 to $95.81. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 9 | Derivative | Stock Option (Right to Buy Common Stock) | 2023-05-09 | M | D | 30,000 | $0.00 | 99,130 | D | $67.81 · 2013-11-15 to 2023-05-14 | 30,000 Common Stock | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F8) Reflects the number of options outstanding after the transactions from this specific stock option grant. |
| 10 | Derivative | Stock Option (Right to Buy Common Stock) | 2023-05-09 | M | D | 30,000 | $0.00 | 69,130 | D | $67.81 · 2013-11-15 to 2023-05-14 | 30,000 Common Stock | (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F8) Reflects the number of options outstanding after the transactions from this specific stock option grant. |